B C Liang - JoVE Visualize

Showing results (21-30 of 31) with videos related to

Pageof 4

Sort By:

Muscle & Nerve|January 1, 1994

Paraneoplastic pseudo-obstruction, mononeuropathy multiplex, and sensory neuronopathyB C Liang, J W Albers, A A Sima, et al.

Cell|December 11, 1992

A Drosophila model for xeroderma pigmentosum and Cockayne's syndrome: haywire encodes the fly homolog of ERCC3, a human excision repair geneL C Mounkes, R S Jones, B C Liang, et al.

Neurology|March 1, 1994

Evidence of allelic imbalance of chromosome 6 in human astrocytomasB C Liang, D A Ross, H S Greenberg, et al.

Genetics and Molecular Research : GMR|December 5, 2015

Weak cation magnetic separation technology and MALDI-TOF-MS in screening serum protein markers in primary type I osteoporosisX L Shi, C W Li, B C Liang, et al.

Neurology|May 1, 1995

Age influences chemotherapy response in astrocytomasR Grant, B C Liang, M A Page, et al.

In Vitro Cellular & Developmental Biology. Animal|July 14, 1998

Receptor expression, cytogenetic, and molecular analysis of six continuous human glioma cell linesC A Kruse, M Varella-Garcia, B K Kleinschmidt-Demasters, et al.

Leukemia & Lymphoma|December 25, 2003

Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphomaS George, F Yunus, D Case, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003

Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphomaJ M Vose, M Crump, H Lazarus, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancerF A Holmes, J A O'Shaughnessy, S Vukelja, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2002

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapyM D Green, H Koelbl, J Baselga, et al.

Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:

Pageof 4

Muscle & Nerve|January 1, 1994

Paraneoplastic pseudo-obstruction, mononeuropathy multiplex, and sensory neuronopathyB C Liang, J W Albers, A A Sima, et al.

Cell|December 11, 1992

A Drosophila model for xeroderma pigmentosum and Cockayne's syndrome: haywire encodes the fly homolog of ERCC3, a human excision repair geneL C Mounkes, R S Jones, B C Liang, et al.

Neurology|March 1, 1994

Evidence of allelic imbalance of chromosome 6 in human astrocytomasB C Liang, D A Ross, H S Greenberg, et al.

Genetics and Molecular Research : GMR|December 5, 2015

Weak cation magnetic separation technology and MALDI-TOF-MS in screening serum protein markers in primary type I osteoporosisX L Shi, C W Li, B C Liang, et al.

Neurology|May 1, 1995

Age influences chemotherapy response in astrocytomasR Grant, B C Liang, M A Page, et al.

In Vitro Cellular & Developmental Biology. Animal|July 14, 1998

Receptor expression, cytogenetic, and molecular analysis of six continuous human glioma cell linesC A Kruse, M Varella-Garcia, B K Kleinschmidt-Demasters, et al.

Leukemia & Lymphoma|December 25, 2003

Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphomaS George, F Yunus, D Case, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003

Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphomaJ M Vose, M Crump, H Lazarus, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancerF A Holmes, J A O'Shaughnessy, S Vukelja, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2002

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapyM D Green, H Koelbl, J Baselga, et al.

Pageof 4